Evidence map›Paper›PMID 27436416›Full record

ArticleScientific reports2016

Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1.

Yuki Murakami, Takaaki Ishibashi, Eiichi Tomita, Yukio Imamura, Tomoyuki Tashiro, Kanitta Watcharanurak, Makiya Nishikawa, Yuki Takahashi, Yoshinobu Takakura, Satoko Mitani and 8 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. The Footprint of Kynurenine Pathway in Cardiovascular Diseases.International journal of tryptophan research : IJTR · 2022
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Yuki MurakamiHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Takaaki IshibashiHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Eiichi TomitaDepartment of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan.
Yukio ImamuraHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Tomoyuki TashiroHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Kanitta WatcharanurakDepartment of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Makiya NishikawaDepartment of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Yuki TakahashiDepartment of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Yoshinobu TakakuraDepartment of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Satoko MitaniHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Hidetsugu FujigakiDepartment of Medical Science and Technology, Faculty of Health Sciences, Hiroshima International University, Hiroshima, 739-2695, Japan.
Yoshiji OhtaDepartment of Medical Sciences Innovation, Fujita Health University Graduate School of Health Sciences, Aichi 470-1192, Japan.
Hisako KuboHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Takayoshi MamiyaDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijyo University, Aichi 468-8503, Japan.
Toshitaka NabeshimaJapanese Drug Organization of Appropriate Use and Research, Aichi 468-0069, Japan.
Hyoung-Chun KimNeuropsychopharmacology &Toxicology Program, College of Pharmacy, Kangwon National University, Gangwon 200-701, Republic of Korea.
Yasuko YamamotoHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Kuniaki SaitoHuman Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Kyoto University · JPFujita Health University · JPKyoto Pharmaceutical University · JPGifu Municipal Hospital · JPGifu University of Medical Science · JPHiroshima International University · JPKangwon National University · KRMeijo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is known to occur frequently in chronic hepatitis C viral (HCV) patients receiving interferon (IFN)-α therapy. In this study, we investigated whether indoleamine 2,3-dioxygenase1 (IDO1)-mediated tryptophan (TRP) metabolism plays a critical role in depression occurring as a side effect of IFN-α therapy. Increases in serum kynurenine (KYN) and 3-hydroxykynurenine (3-HK) concentrations and in the ratios of KYN/TRP and 3-HK/kynurenic acid (KA) were much larger in depressive HCV patients than in non-depressed patients following therapy. Furthermore, transfection of a plasmid continuously expressing murine IFN-γ into normal mice significantly increased depression-like behavior. IFN-γ gene transfer also resulted in a decrease in serum TRP levels in the mice while KYN and 3-HK levels were significantly increased in both serum and frontal cortex. Genetic deletion of IDO1 in mice abrogated both the increase in depression-like behavior and the elevation in TRP metabolites' levels, and the turnover of serotonin in the frontal cortex after IFN-γ gene transfer. These results indicate that the KYN pathway of IDO1-mediated TRP metabolism plays a critical role in depressive symptoms associated with IFN-α therapy.

Indexed as

AnimalsBehavior, AnimalDepressionEnzyme InductionFemaleFrontal LobeHepatitis C, ChronicHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-alphaInterferon-gammaKynurenineMaleMetabolomeMice, Inbred C57BLMiddle AgedIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-alphaInterferon-gammaKynurenineSerotoninTryptophan

Identifiers

PMID27436416
PMCPMC4951771
OpenAlexW2480881242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.